Topical Anti-inflammatory Composition for Skin Inflammation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for skin inflammation targeting the PLA2 family via oral administration are suboptimal due to systemic side effects and low potency, making them unsuitable for topical application, which requires high potency and rapid clearance to avoid systemic effects.
Innovation Solution
A pharmaceutical composition comprising the compound 3-{4-[2-{5-chloro-1-(diphenylmethyl)-2-[2-({[2-(trifluoromethyl)benzyl]sulfonyl}amino)ethyl]-1H-indol-3-yl}ethyl]sulfonyl}phenyl}propanoic acid or its pharmaceutically acceptable salts, formulated for topical administration, which penetrates deeper skin layers and exhibits anti-inflammatory action.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If oral administration is used to treat skin inflammation with PLA2 inhibitors, then systemic availability is achieved, but systemic side effects and low potency occur
Solution Approach 1:
The invention extracts the active compound from systemic circulation and delivers it directly to the target site (skin). By using topical administration instead of oral route, the drug is applied locally to the skin where inflammation occurs, avoiding first-pass metabolism and systemic distribution, thereby eliminating gastrointestinal side effects while achieving high local concentration and potency.
Solution Approach 2:
The invention uses a topical formulation as an intermediary delivery system that enables the compound to reach the skin directly. The formulation acts as a mediator between the compound and the target tissue, facilitating localized delivery without requiring systemic absorption, thus avoiding systemic side effects while maintaining therapeutic efficacy.
2Quantity of substance
If oral administration is used, then dosage can be increased to compensate for low potency, but this increases systemic exposure and side effects
Solution Approach 1:
The invention applies the compound locally to the skin with high potency, creating a localized high concentration at the target site. This local quality approach allows using a much smaller total dose compared to oral administration, because the drug is concentrated exactly where needed rather than distributed systemically, thereby avoiding the need to increase dosage which would otherwise lead to increased systemic exposure and side effects.
3Object-affected harmful factors
If topical administration is used, then systemic side effects are avoided, but high potency and rapid clearance are required for effectiveness
Solution Approach 1:
The invention changes the key parameter of potency to a very high level specifically for the topical compound. The compound is designed with nanomolar IC50 values (extremely high potency) to ensure that even at low local concentrations achieved through topical application, sufficient therapeutic effect is obtained. This parameter change in potency compensates for the limited delivery efficiency of topical route while maintaining low systemic exposure.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The compound effectively reduces skin inflammation when applied topically, avoiding systemic side effects and demonstrating higher potency than traditional PLA2 inhibitors, with formulations optimized for enhanced dermal penetration and localized action.
Implementation Method 1
the compound of the present invention, an inhibitor of cPLA2α developed for oral administration, to be efficacious and well tolerated when delivered as part of a composition for topical administration
Implementation Method 2
Cytosolic phospholipase A2 (cPLA2), a member of the phospholipase A2 (PLA2) family, releases arachidonic acid from the phospholipid membrane and is the rate-limiting enzyme in the biosynthesis of prostaglandins (PGs), thromboxanes (Txs) and leukotrienes (LTs)
Data Source
AI summary
The present invention relates to a pharmaceutical composition for topical administration comprising a compound of formula I, 3-{4-[2-{5-chloro-1-(diphenylmethyl)-2-[2-({[2-(trifluoromethyl)benzyl]sulfonyl}amino)ethyl]-1H-indol-3-yl}ethyl]sulfonyl}phenyl}propanoic acid:or pharmaceutically acceptable salts thereof; and to methods of treating inflammation comprising topical administration of a compositions comprising a compound of formula I.